Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Aug 8:4:212.
doi: 10.3389/fonc.2014.00212. eCollection 2014.

Monitoring residual disease in the ph-negative myeloproliferative neoplasms post-allogeneic stem cell transplantation: more mutations and more methodologies

Stephen E Langabeer  1 , Karl Haslam  1 , Eibhlin Conneally  2
Affiliations
Review

Monitoring residual disease in the ph-negative myeloproliferative neoplasms post-allogeneic stem cell transplantation: more mutations and more methodologies

Stephen E Langabeer et al. Front Oncol. .
No abstract available

Keywords: CALR; JAK2 V617F; allogeneic stem cell transplantation; digital PCR; myeloproliferative neoplasms; next generation sequencing; residual disease.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Summary of methodologies for monitoring MPN-specific mutations post-allogeneic stem cell transplantation. ASCT, allogeneic stem cell transplantation; MPN, myeloproliferative neoplasm; qPCR, quantitative polymerase chain reaction; NGS, next generation sequencing; and dPCR, digital polymerase chain reaction.
See this image and copyright information in PMC

References

    1. Santos FP, Verstovsek S. Therapy with JAK2 inhibitors for myeloproliferative neoplasms. Hematol Oncol Clin North Am (2012) 26:1083–9910.1016/j.hoc2012.07.008 - DOI - PMC - PubMed
    1. Fleischman AG, Maziarz RT. Hematopoietic stem cell transplantation for myelofibrosis: where are we now? Curr Opin Hematol (2013) 20:130–610.1097/MOH.0b013e32835dd862 - DOI - PubMed
    1. Steckel NK, Koldehoff M, Ditschkowski M, Beelen DW, Elmaagacli AH. Use of the activating gene mutation (Val617Phe) JAK2 as a minimal residual disease marker in patients with myelofibrosis and myeloid metaplasia after allogeneic stem cell transplantation. Transplantation (2007) 83:1518–2010.1097/01.tp.0000263393.65764.f4 - DOI - PubMed
    1. Alchalby H, Badbaran A, Zabelina T, Kobbe G, Hahn J, Wolff D, et al. Impact of JAK2 V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis. Blood (2010) 116:3572–8110.1182/blood-2009-12-260588 - DOI - PubMed
    1. Lange T, Edelmann A, Siebolts U, Krahl R, Nehring C, Jäkel N, et al. JAK2 p.V617F allele burden in myeloproliferative neoplasms one month after allogeneic stem cell transplantation significantly predicts outcome and risk of relapse. Haematologica (2013) 98:722–810.3324/haematol.2012.076901 - DOI - PMC - PubMed